TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
-5.03%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.81B
AUM Growth
+$296M
(+20%)
Cap. Flow
+$419M
Cap. Flow
% of AUM
23.17%
Top 10 Holdings %
Top 10 Hldgs %
39.2%
Holding
208
New
25
Increased
78
Reduced
31
Closed
6
Top Buys
| 1 |
Dynavax Technologies
DVAX
|
$50.6M |
| 2 |
Galapagos
GLPG
|
$45.2M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$33.1M |
| 4 |
Spyre Therapeutics
SYRE
|
$33.1M |
| 5 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.6M |
| 2 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
$7.23M |
| 3 |
GRAL
GRAIL, Inc. Common Stock
GRAL
|
$4.82M |
| 4 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$4.72M |
| 5 |
Seer Inc
SEER
|
$1.52M |
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Technology | 1.25% |
| 3 | Communication Services | 1.23% |
| 4 | Consumer Discretionary | 0.99% |
| 5 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Hewlett Packard
HPE
$30.4B
| $687K | 0.04% |
44,547
-1,844
| -4% | -$28.5K |
|
177
Corbus Pharmaceuticals
CRBP
$123M
| $677K | 0.04% |
127,520
-115,133
| -47% | -$611K |
|
178
Kura Oncology
KURA
$730M
| $660K | 0.04% |
100,000
| – | – |
|
179
Puma Biotechnology
PBYI
$260M
| $592K | 0.03% |
200,000
| – | – |
|
180
Astria Therapeutics
ATXS
$405M
| $534K | 0.03% |
100,000
| – | – |
|
181
Lexicon Pharmaceuticals
LXRX
$389M
| $530K | 0.03% |
1,150,268
+300,000
| +35% | +$138K |
|
182
Passage Bio
PASG
$24.3M
| $530K | 0.03% |
75,000
| – | – |
|
183
Outlook Therapeutics
OTLK
$42.7M
| $488K | 0.03% |
400,000
+217,498
| +119% | +$265K |
|
184
Reviva Pharmaceuticals
RVPH
$30.2M
| $487K | 0.03% |
510,329
+340,329
| +200% | +$325K |
|
185
BioAtla
BCAB
$29.5M
| $477K | 0.03% |
1,374,076
| – | – |
|
186
Atara Biotherapeutics
ATRA
$92.2M
| $447K | 0.02% |
75,196
| – | – |
|
187
Standard BioTools
LAB
$497M
| $440K | 0.02% |
407,755
| – | – |
|
188
Century Therapeutics
IPSC
$43M
| $428K | 0.02% |
900,000
| – | – |
|
189
Amylyx Pharmaceuticals
AMLX
$886M
| $354K | 0.02% |
100,000
| – | – |
|
190
Cassava Sciences
SAVA
$105M
| $300K | 0.02% |
+200,000
| New | +$300K |
|
|
GRAL
191
GRAIL, Inc. Common Stock
GRAL
$1.24B
| $289K | 0.02% |
11,300
-188,700
| -94% | -$4.82M |
|
192
Kodiak Sciences
KOD
$460M
| $281K | 0.02% |
+100,000
| New | +$281K |
|
193
MacroGenics
MGNX
$135M
| $278K | 0.02% |
218,856
| – | – |
|
194
Quince Therapeutics
QNCX
$85.4M
| $245K | 0.01% |
+184,383
| New | +$245K |
|
195
Invivyd
IVVD
$209M
| $242K | 0.01% |
400,000
+69,828
| +21% | +$42.3K |
|
196
NextCure
NXTC
$13M
| $194K | 0.01% |
33,679
-24,654
| -42% | -$142K |
|
197
Metagenomi
MGX
$68.3M
| $184K | 0.01% |
+134,978
| New | +$184K |
|
|
JBIO
198
Jade Biosciences, Inc. Common Stock
JBIO
$257M
| $175K | 0.01% |
+1,993
| New | +$175K |
|
199
Athira Pharma
ATHA
$15.6M
| $171K | 0.01% |
600,000
| – | – |
|
200
Seres Therapeutics
MCRB
$165M
| $143K | 0.01% |
+10,195
| New | +$143K |
|